According to a report by Altus Market Research titled, “Kidney Cancer Drugs Global Market 2022 Share, Growth 2030 By Type: (Renal Cell Carcinoma (RCC); Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)); By Product: (Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient)”, the global kidney cancer drugs market reached a value of nearly $3,600.5 million in 2020, having increased at a compound annual growth rate (CAGR) of 1.2% since 2015. The market is expected to grow from $3,600.5 million in 2020 to $4,518.4 million in 2025 at a compound annual growth rate of 4.6%. The market is then expected to grow at a CAGR of 2.1% from 2025 and reach $5,025.3 million in 2030.
Growth in the historic period in the kidney cancer drugs market resulted from increased healthcare expenditure, rapid growth in elderly population, increase in pharmaceutical R&D expenditure, and advances in cancer drug discovery. The market was restrained by patent expiration of drugs, challenges due to regulatory changes, and low healthcare access. Going forward, increasing geriatric population, rise in healthcare expenditure, rise in acquisitions and partnerships for drug development, and high potential of emerging economies will drive the growth in the vaccines market. Factors that could hinder the growth of the market in the future include reduction in free trade, high costs of drugs, and coronavirus pandemic.
The kidney cancer drugs market is segmented by type into renal cell carcinoma (RCC), and transitional cell carcinoma (TCC) or urothelial cell carcinoma (UCC). The renal cell carcinoma (RCC) segment was the largest segment of the kidney cancer drugs market segmented by type, accounting for 72.1% of the total in 2020. Going forward, the transitional cell carcinoma (TCC) or urothelial cell carcinoma (UCC) segment is expected to be the fastest growing segment in the kidney cancer drugs market segmented by type, at a CAGR of 5.7% during 2020-2025.
The kidney cancer drugs market is also segmented by product into nexavar (sorafenib), sutent (sunitinib), afinitor (everolimus), votrient (pazopanib), avastin (bevacizumab), inlyta (axitinib), torisel (temsirolimus), proleukin (aldesleukin), and others. The other products segment was the largest segment of the kidney cancer drugs market segmented by product, accounting for 39.4% of the total in 2020. Going forward, the Inlyta (Axitinib) segment is expected to be the fastest growing segment in the kidney cancer drugs market segmented by product, at a CAGR of 7.6% during 2020-2025.
Request Research Sample with Latest Industry Insights (299+ Pages Report): https://altusmarketresearch.com/reports/sample/43188
The kidney cancer drugs market is also segmented by end users into hospitals, clinics, research center, and others. The hospitals segment was the largest segment of the kidney cancer drugs market segmented by end users, accounting for 52.5% of the total in 2020. Going forward, the research center segment is expected to be the fastest growing segment in the kidney cancer drugs market segmented by end users, at a CAGR of 6.0% during 2020-2025.
Market Growth by Region:
North America was the largest region in the kidney cancer drugs market, accounting for 46.6% of the total in 2020. It was followed by the Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the kidney cancer drugs market will be South America and Africa where growth will be at CAGRs of 8.5% and 6.6% respectively during 2020-2025. These will be followed by Middle East and North America, where the markets are expected to register CAGRs of 6.2% and 5.5% respectively during 2020-2025.
COVID-19 Impact
The kidney cancer drugs market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries. COVID-19 has caused clinical trial delays for kidney cancer drugs, and has resulted in low usage of kidney cancer drugs. Due to worldwide lockdown, production is also being halted which is causing supply chain issues. The COVID-19 pandemic is a major inhibitor for the growth of kidney cancer drug trials during the period. The coronavirus outbreak is disrupting clinical research across the globe and has affected the management of ongoing trials and planning of future trials for oncology including kidney cancer drugs. According to a survey conducted by the Cancer Research Institute (CRI) and IQVIA in March and April 2020, out of 36 investigators institutes only 20% or 14% of institutions enrolled patients with the usual rate in the USA and Europe. In addition to this, analysis from ClinicalTrails.gov indicated that over 200 interventional studies were suspended in March and April 2020 because of COVID-19.
Market Growth by Key Players:
The kidney cancer drugs market is highly consolidated with a small number of global players dominating the market. The key players in the market are focusing on expanding their operational and business presence in the kidney cancer drugs market through development of advanced technologies, strategic collaborations and acquisition and new product launch to meet the global demand. The top ten competitors in the market made up to 89.83% of the total market in 2020. The key players in the kidney cancer drugs market includes Pfizer Inc., Novartis AG, Exelixis, Inc., F. Hoffmann-La Roche AG, and Bristol Myers Squibb Company.
Player-adopted strategies in the vaccines market includes strategic collaboration and acquisitions for research & development activities, investments, strategic partnerships for production new kidney cancer drugs, establishment of new manufacturing facilities, and new product launches to meet the global demand.
Future Investment Opportunities:
The top opportunities in the kidney cancer drugs market segmented by type will arise in renal cell carcinoma (RCC) segment, which will gain $594.1 million of global annual sales by 2025. The top opportunities in the kidney cancer drugs market segmented by product will arise in Inlyta (Axitinib) segment, which will gain $349.0 million of global annual sales by 2025. The top opportunities in the kidney cancer drugs market segmented by end users will arise in hospitals segment, which will gain $457.0 million of global annual sales by 2025. The kidney cancer drugs market size will gain the most in the USA at $502.1 million.
Market: Trend-based Strategies
Market-trend-based strategies for the vaccines includes adopting 3D technology in manufacturing drugs and create models to provide matrix interactions and more personalized treatments, investing in biomarkers to produce more effective drugs in a smaller time frame, launching or adopting new treatment developments to treat patients and give them a longer survival time, improve treatment by offering personalized medicine, invest in AI solutions, to save drug development time and accurately diagnose a patient, and collaborating and partnering with other companies or government bodies to accelerate the development of new drugs.
To take advantage of these opportunities, Altus Market Research recommends the kidney cancer drugs companies to on the expansion of cell and gene therapy for kidney cancers, scale up through collaborations and partnerships, expand in developed markets, setup authorized distributors and sales representatives, offer bundled payments, provide competitively priced offerings in low-income countries, participate in trade shows and events, increase visibility through SEO campaigns, leverage social media, focus on increasing awareness, targeting aging population, and targeting hospitals and clinics to spread awareness.
The report covers the following chapters
Executive Summary – The executive summary section of the report gives a brief overview and summary of the report
Report Structure – This section gives the structure of the report and the information covered in the various sections.
Introduction – The introduction section of the report gives brief introduction about segmentation by geography, segmentation by type, segmentation by product and segmentation by end users.
Market Characteristics – The market characteristics section of the report defines and explains the kidney cancer drugs market. This chapter also defines and describes goods and related services covered in the report.
Trends And Strategies – This section describes the major trends shaping the global kidney cancer drugs market. This section also highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
Impact of COVID-19 – This section describes the impact of COVID-19 on the kidney cancer drugs market.
Global Market Size And Growth – This section contains the global historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional Analysis – This section contains the historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
Segmentation – This section contains the market values (2015-2030) and analysis for different segments.
Global Macro Comparison – The global kidney cancer drugs market comparison with macro-economic factors gives the kidney cancer drugs market size, percentage of GDP, and average kidney cancer drugs market expenditure.
Regional Market Size and Growth – This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025) and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
Competitive Landscape – This section covers details on the competitive landscape of the global kidney cancer drugs market, estimated market shares and company profiles for the leading players.
Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, Arlak Biotech, Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Celon Pharma, Amgen Inc., Biocon Ltd, Rani Therapeutics, Eli Lilly and Company, Abbott Laboratories, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc, AVEO Oncology, Eurofarma Laboratórios S.A., TUTEUR Argentina, Pierre Fabre Group, Celnova Pharma, Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX
